Echo Therapeutics Schedules Meeting with Platinum-Montaur Next Week, Still Considering Licenses

Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its needle-free Symphony® CGMSystem as a non-invasive, wireless, continuous glucose monitoring system,announced that the independent members of the Board of Directors and Mr.Robert F. Doman, the Executive Chairman and Interim Chief Executive Officer,today sent a letter to its shareholder, Platinum-Montaur Life Sciences, LLC,in response to an August 30, 2013 public communication made byPlatinum-Montaur and its affiliated funds.  In addition, Echo has communicatedwith Platinum-Montaur to discuss the matters raised in the August 30, 2013communication.  The Company and Platinum-Montaur have scheduled a meeting fornext week.As Echo has previously announced, it continues to consider and seek to enterinto collaborations or licenses regarding the future development anddistribution of its products and remains willing to enter into discussionsregarding potential collaborations or licenses.